Your browser doesn't support javascript.
loading
Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity.
Flaherty, Stephen E; Bezy, Olivier; Zheng, Wei; Yan, Dong; Li, Xiangping; Jagarlapudi, Srinath; Albuquerque, Bina; Esquejo, Ryan M; Peloquin, Matthew; Semache, Meriem; Mancini, Arturo; Kang, Liya; Drujan, Doreen; Breitkopf, Susanne B; Griffin, John D; Jean Beltran, Pierre M; Xue, Liang; Stansfield, John; Pashos, Evanthia; Shakey, Quazi; Pehmøller, Christian; Monetti, Mara; Birnbaum, Morris J; Fortin, Jean-Philippe; Wu, Zhidan.
Affiliation
  • Flaherty SE; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Bezy O; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Zheng W; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Yan D; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Li X; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Jagarlapudi S; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Albuquerque B; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Esquejo RM; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Peloquin M; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Semache M; Domain Therapeutics North America, Montréal, QC, Canada.
  • Mancini A; Domain Therapeutics North America, Montréal, QC, Canada.
  • Kang L; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Drujan D; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Breitkopf SB; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Griffin JD; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Jean Beltran PM; Machine Learning and Computational Sciences, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Xue L; Machine Learning and Computational Sciences, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Stansfield J; Biostatistics, Early Clinical Development, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Pashos E; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Shakey Q; Biomedicine design, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Pehmøller C; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Monetti M; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Birnbaum MJ; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Fortin JP; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.
  • Wu Z; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA. Zhidan.wu@pfizer.com.
Nat Commun ; 14(1): 3953, 2023 07 04.
Article in En | MEDLINE | ID: mdl-37402735
Urocortin 2 (UCN2) acts as a ligand for the G protein-coupled receptor corticotropin-releasing hormone receptor 2 (CRHR2). UCN2 has been reported to improve or worsen insulin sensitivity and glucose tolerance in vivo. Here we show that acute dosing of UCN2 induces systemic insulin resistance in male mice and skeletal muscle. Inversely, chronic elevation of UCN2 by injection with adenovirus encoding UCN2 resolves metabolic complications, improving glucose tolerance. CRHR2 recruits Gs in response to low concentrations of UCN2, as well as Gi and ß-Arrestin at high concentrations of UCN2. Pre-treating cells and skeletal muscle ex vivo with UCN2 leads to internalization of CRHR2, dampened ligand-dependent increases in cAMP, and blunted reductions in insulin signaling. These results provide mechanistic insights into how UCN2 regulates insulin sensitivity and glucose metabolism in skeletal muscle and in vivo. Importantly, a working model was derived from these results that unifies the contradictory metabolic effects of UCN2.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United kingdom